After an uncomfortably long hiatus from The Daily Sign-Out, I'm back. Nothing serious, just summertime distractions (fun!) and intense preparation for our lab's upcoming CAP inspection (not so fun). Anyway, here's an interesting item that I recently (re-) discovered under my stack of journals, papers, flotsam that I thought notable. Stayed tuned to this blog because I've collected some mighty interesting cases that I'll be sharing in the weeks ahead. Thanks for reading!
Methylation of any two of four genes — APC, RASSF1A, CDKN2A and CDH13 — in the tumor and draining lymph nodes is predictive of a poor prognosis in patients with stage I NSCLC and may identify a group of patients who might benefit from combined treatment with a low-dose DNA methyltransferase inhibitor and an histone deacetylase inhibitor (HDACI). You can get a free copy of the article by clicking here. There's also a nice accompanying podcast of the article if you're more of an aural learning (you know who you are). By the way, I love this journal! If you're interested in cancer, browse through the issues and I'm sure you'll find something to pique your interest.